An observational study in Functional Gastrointestinal Disorders, sponsored by Massachusetts General Hospital. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by Massachusetts General Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 200 studies in Gastrointestinal Diseases with a site in United States — 32 open to participants now, 42 under way, 5 of them phase 3. Gastrointestinal Diseases · United States.
Among the 200 studies in Gastrointestinal Diseases with a site in United States, this one is the 18th largest by planned enrollment of the 57 observational ones that give a count, is one of 11 that started in 2018, is one of 58 observational ones, reaches primary completion later than 10 of the 41 other live ones, and was the 160th registered.
549 studies on the registry are indexed under Gastrointestinal Diseases; 102 are open to participants now.
Browse Gastrointestinal Diseases studies →32 of the 200 studies in Gastrointestinal Diseases with a site in United States are open now. Recruiting first, the newest first:
Virginia Polytechnic Institute and State University · Sites in United States
Ages 6 mo+ · Healthy volunteers
Northwestern University · Sites in United States
Ages 18+
Baylor College of Medicine · Sites in United States
Ages 7–12
Christopher C. Thompson, MD, MSc · Sites in United States
Ages 18–90
Zealand Pharma · Sites in United States, Austria, Belgium and 11 more countries
Ages 18–90
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 66 Gastrointestinal Diseases studies recruiting now, 30 (45%) set no upper age limit and 23 (35%) stop at 75 or younger; 19 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
200 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 39 · Phase 3 27 · Phase 4 7
First in 1995; this study’s year is marked. 11 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 700 is above the median of 350 across 148 observational studies indexed under Gastrointestinal Diseases.
Median enrollment 90 across the 141 interventional studies, 250 across the 57 observational. Of the 138 that completed or were terminated, 52 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 200 have an industry lead sponsor. The 10 most frequent:
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
Massachusetts General Hospital has 6 studies filed under Gastrointestinal Diseases — fewer than ten, so there is no comparison to draw.
15 of the studies in Gastrointestinal Diseases with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05776277Phase 3Cook MyoSiteIltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury | 2026-12 |
| NCT05501028Massachusetts General HospitalNLP to Aid in the Evaluation and Diagnosis of FGIDs | 2026-12 |
| NCT05212129Medical College of WisconsinAuricular Vagal Nerve Stimulation for Hypermobile Ehlers-Danlos Syndrome | 2026-12-31 |
| NCT05489237IDRX, Inc., a wholly owned subsidiary of GSK, LLCFirst-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors | 2027-03-10 |
| NCT07351071Medtronic - MITGPost-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections | 2027-04-30 |
Add all 15 to your calendar (.ics) → With an account.
Among the 200 studies in Gastrointestinal Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study has two arms, where the same natural language processing (NLP) and probabilistic graphical modeling technology will be utilized on patients' report of symptoms in both arms. The clinical arm is focused on patients presenting for consultation with a gastroenterologist. The endoscopy arm is focused generally on patients presenting for a diagnostic endoscopy, with the goal of capturing Functional Gastrointestinal Disorder (FGID) patients prior to diagnosis.
Group 1: Patients who are scheduled for a consult in the MGH Gastroenterology Unit
Group 2: Patients who are scheduled for a diagnostic endoscopy in the MGH Gastroenterology Unit
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Latent themes present in patient descriptions of FGIDs symptoms
Latent themes present in patient descriptions of FGIDs symptoms as generated by machine learning as well as quantitative comparisons to traditional metrics of patient descriptions including Rome IV criteria and patient descriptions of severity.
Time frame: 08/09/2018-08/09/2023
Plan to share: Undecided
No publications or documents are linked to this record.
Started Aug 2018 (actual). Primary completion is estimated for Dec 2026, 100 months after the start.
Of 66 observational studies under Gastrointestinal Diseases, half reached primary completion within 82 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 155. This study's planned 100 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →